Shanu Modi
Tracked across 1 events · 16 articles · First seen May 15, 2026 · Last active May 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Shanu Modi, a medical oncologist and principal investigator for the DESTINY-Breast11 trial, provided expert commentary on the significance of Trastuzumab deruxtecan's new indications for breast cancer treatment.
May 15, 2026 · 16 articles
ERGEN INTELLIGENCE
Track Shanu Modi live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard